Vaccine Efficacy ag Rotavirus Diarrhoea; Vaccine Given w Routine Childhood Vaccinations in Healthy African Infants - Full Text View

Sponsored by:	GlaxoSmithKline
Information provided by:	GlaxoSmithKline
ClinicalTrials.gov Identifier:	NCT00241644

Purpose

The primary objective of this study is to determine if the GSK Biologicals' HRV vaccine (pooled HRV groups) given concomitantly with routine EPI vaccinations can prevent severe rotavirus gastroenteritis (≥11 on the 20-point Vesikari scoring system [Ruuska, 1990]) caused by the circulating wild-type RV strains during the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 5.

The primary objective will be reached if the lower limit of the 95% confidence interval (CI) on vaccine efficacy is >0%.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Condition	Intervention	Phase
Prophylaxis Rotavirus Gastroenteritis Caused by Rotavirus	Biological: GSK Biologicals' HRV vaccine Biological: Placebo	Phase III

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Efficacy Study
Official Title:	Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants

Resource links provided by NLM:

MedlinePlus related topics: Gastroenteritis

U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:

Occurrence of severe rotavirus (RV) gastroenteritis (GE) (score >= 11 on a 20-point Vesikari scoring system [Ruuska, 1990]) caused by the circulating wild-type RV strains in pooled HRV groups versus the placebo group. [ Time Frame: During the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 6 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Occurrence of severe RV GE caused by the circulating wild-type RV strains of G1 serotype. [ Time Frame: During the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 6 ] [ Designated as safety issue: Yes ]
Occurrence of severe RV GE caused by the circulating wild-type RV strains of non-G1 serotype [ Time Frame: During the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 6 ] [ Designated as safety issue: Yes ]
Occurrence of any RV GE caused by the circulating wild-type RV strains [ Time Frame: During the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 6. ] [ Designated as safety issue: Yes ]
Occurrence of severe RV GE caused by the circulating wild-type RV strains. [ Time Frame: During the period starting from Dose 1 of the study vaccine until Visit 6 ] [ Designated as safety issue: Yes ]
In South Africa, occurrence of severe RV GE caused by the circulating wild-type RV strains for the subset of subjects who were fully vaccinated (at least 2 weeks post HRV dose 2 or 3) before the beginning of the RV season. [ Time Frame: During the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 6. ] [ Designated as safety issue: Yes ]
Occurrence of severe GE. [ Time Frame: During the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 6 ] [ Designated as safety issue: Yes ]
For subjects in Cohort 2 South Africa and the cohort in Malawi:Occurrence of severe RV GE caused by the circulating wild-type RV strains [ Time Frame: During the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 7, and from Visit 6 to Visit 7. ] [ Designated as safety issue: Yes ]
For subjects in Cohort 2 South Africa and the cohort in Malawi: Occurrence of hospitalisation and/or supervised re-hydration therapy in a medical facility for RV GE caused by the circulating wild-type RV strains [ Time Frame: During the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 7, and from Visit 6 to Visit 7. ] [ Designated as safety issue: Yes ]
For subjects in Cohort 2 South Africa and the cohort in Malawi: Occurrence of severe RV GE caused by the circulating wild-type RV strains of G1 serotype [ Time Frame: During the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 7, and from Visit 6 to Visit 7. ] [ Designated as safety issue: Yes ]
For subjects in Cohort 2 South Africa and the cohort in Malawi: Occurrence of severe RV GE caused by the circulating wild-type RV strains of non-G1 serotype [ Time Frame: During the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 7, and from Visit 6 to Visit 7 ] [ Designated as safety issue: Yes ]
For all subjects, occurrence of adverse events (AEs)/serious adverse events (SAEs) leading to drop-out [ Time Frame: Throughout the entire study period. ] [ Designated as safety issue: Yes ]
For all subjects, occurrence of SAEs. [ Time Frame: Throughout the entire study period ] [ Designated as safety issue: Yes ]
In a subset of subjects, seroconversion rate and Geometric Mean concentration (GMC) to anti-rotavirus immunoglobulin A (IgA) antibody. [ Time Frame: At Visit 4 ] [ Designated as safety issue: No ]
In all subjects, seropositivity rate and GMC to anti-rotavirus IgA antibody [ Time Frame: At Visit 4 ] [ Designated as safety issue: No ]
Occurrence of hospitalisation and/or supervised re-hydration therapy (equivalent to WHO plan B or C) in a medical facility for RV GE caused by the circulating wild-type RV strains [ Time Frame: During the period from 2 weeks after the last dose of human rotavirus vaccine (HRV) vaccine or placebo until Visit 6. ] [ Designated as safety issue: Yes ]

Enrollment:	4941
Study Start Date:	October 2005
Study Completion Date:	June 2008
Primary Completion Date:	June 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Group HRV 2-Dose: Experimental Subjects received 1 dose of placebo followed by 2 doses of HRV vaccine given concomitantly with routine EPI vaccines and one dose of placebo	Biological: GSK Biologicals' HRV vaccine Two or Three doses, oral administration Biological: Placebo One or three doses, oral administration.
Group Placebo: Placebo Comparator Subjects received 3 doses of placebo given concomitantly with routine EPI vaccines	Biological: Placebo One or three doses, oral administration.
Group HRV 3-Dose: Experimental Subjects received 3 doses of HRV vaccine given concomitantly with routine Expanded Program of Immunisation (EPI) vaccines	Biological: GSK Biologicals' HRV vaccine Two or Three doses, oral administration

Detailed Description:

The study will have three groups: Group HRV 3-Dose, Group HRV 2-Dose and Group Placebo. Three-dose immunisation will be administered in healthy infants at approximately 6, 10, and 14 weeks of age. Routine EPI vaccinations will be administered concomitantly with the study vaccines. This study will also evaluate immunogenicity and safety relative to the placebo.

Eligibility

Ages Eligible for Study:	5 Weeks to 10 Weeks
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion criteria:

Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
A male or female child between, and including, 5 and 10 weeks of age at the time of the first study vaccination.
Written informed consent obtained from the parent or guardian of the subject who is of legal age
Healthy subjects as established by medical history and clinical examination before entering into the study.
In South Africa, birth weight > 2000 g or if weight unknown, gestation period > 36 weeks.

Exclusion criteria:

Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product
Planned administration of a vaccine not foreseen by the study protocol within 14 days before each dose of study vaccine(s) and ending 14 days after.
Chronic administration (defined as more than 14 days) of immunosuppressants since birth.
History of use of experimental rotavirus vaccine.
Previous routine vaccination except BCG, HBV and OPV vaccination at birth
Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract, intussusception or other medical condition determined to be serious by the investigator.
Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination
History of allergic disease or reaction likely to be exacerbated by any component of the vaccine.
Acute disease at the time of enrolment.
Gastroenteritis within 7 days preceding the first study vaccine administration
Previous confirmed occurrence of RV GE.
A family history of congenital or hereditary immunodeficiency.
Administration of immunoglobulins and/or blood products since birth or planned administration during the study period.
History of any neurologic disorders or seizures.
Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00241644

Locations

Malawi
GSK Investigational Site
Ndirande, Blantyre, Malawi, 3
GSK Investigational Site
Zingwanga, Blantyre, Malawi, 3
GSK Investigational Site
Bangwe, Blantyre, Malawi, 3
GSK Investigational Site
Limbe, Blantyre, Malawi, 3
South Africa
GSK Investigational Site
Tembisa, South Africa
GSK Investigational Site
Brits, South Africa, 0250
GSK Investigational Site
Diepsloot, South Africa
GSK Investigational Site
Mamelodi, South Africa
GSK Investigational Site
Shoshanguve, South Africa
GSK Investigational Site
Mamelodi East, South Africa
GSK Investigational Site
Eldorado Park Ext 9, Soweto, South Africa
GSK Investigational Site
Diepkloof, Soweto, South Africa
GSK Investigational Site
Karenpark, South Africa, 0118
GSK Investigational Site
BRITS, South Africa, 0250

Sponsors and Collaborators

GlaxoSmithKline

Investigators

Study Director:

GSK Clinical Trials

GlaxoSmithKline

More Information

No publications provided

Responsible Party:	GSK ( Study Director )
Study ID Numbers:	102248
Study First Received:	October 18, 2005
Last Updated:	October 16, 2008
ClinicalTrials.gov Identifier:	NCT00241644 History of Changes
Health Authority:	South Africa: Medicines Control Council

Keywords provided by GlaxoSmithKline:

Rotavirus gastroenteritis
HRV vaccine

Study placed in the following topic categories:

Digestive System Diseases
Diarrhea
Gastrointestinal Diseases
Healthy
Gastroenteritis

Additional relevant MeSH terms:

Digestive System Diseases
Gastrointestinal Diseases
Gastroenteritis

ClinicalTrials.gov processed this record on July 06, 2009